The CRISPR/Cas9 patent in Europe Battlefield:Zhang Feng team a core patent was withdrawn

Source: the CRISPR/Cas9 patent in Europe Battlefield:Zhang Feng team a core patent by the withdrawal

Author: Dopine

Gene editing technology CRISPR/Cas9 the rapid development, is moving towards maturity, of which representatives belong to the University of California, Berkeley Jennifer Doudna, the Broad Institute Feng Zhang, etc. Just recently, the journal Nature published two important research papers published a modified version of the Cas9 protein, the new method can effectively reduce“off-target”toxicity, industrial prospects increasingly bright.

This technique of course be a concern, and some even comment on its having ones Nobel strength, at the same time around the technology of the patent Wars is also very confusing. 2018 1 On number 17, the EPO withdrew the Broad Institute a CRISPR/Cas9 core patent–EP2771468, the reason is innovative and a priority date to determine the problem. The article outlines the core of the patent the withdrawal of the event, and introduced Editas Medicine R & D pipeline.

1、the EPO to withdraw the Broad Institute as a core patent

The European Union, the United States and other regions in the CRISPR/Cas9 patent war the main core is the Broad Institute Feng Zhang team, the University of California at Berkeley on behalf of the international team. University of California at Berkeley on behalf of the international team is the CRISPR/Cas9 technology is a major discovery, do a lot of the basis of early research; Broad Institute Feng Zhang team for the technology application and promotion do quite a lot of work.

the CRISPR/Cas9 patent war: Europe Battlefield

The European Union, the European Patent Office the CRISPR/Cas9 technology licensed to the University of California at Berkeley on behalf of the international team patent number: EP13793997B1, the Claim comprises the CRISPR for prokaryotic cells, prokaryotic, eukaryotic cells and eukaryotic organisms. This is for Zhang Feng speaking, the innovative and the priority date of determination is particularly important, the EPO withdrew the Broad Institute a CRISPR/Cas9 core patent based on the following points:

• Patents lack of novelty;
• The priority date determines the non-compliance; and
• Zhang Feng, the team and the Rockefeller University Luciano Marraffini between disputes.

Zhang Feng, the team in several other European application of the CRISPR/Cas9 patent also facing the above problems, this several patents also is likely to fail.

Then, Zhang Feng will be how to do? Maybe is the following:

• Filed an appeal, currently the Broad Institute have filed an appeal; and
• With the Rockefeller agreed.

2018 1 on No. 15, Broad Institute official website issued a message, said the Broad Institute and Rockefeller agree, the two sides is a CRISPR/Cas9-related patent Co-inventor, the patent relates to US 8,697,359, a number of the PCT application: PCT/US2013/074667, PCT/US2013/074691, PCT/US2013/074736, PCT/US2013/074743, PCT/US2013/074812, PCT/US2013/074819, PCT/US2013/074825, PCT/US2013/074790 or PCT/US2013/074800 as well as patent US 15/349,603 in. This is for Zhang Feng, the team is concerned, is a positive trend, but the team of the European patent application is still hanging.

2、speak Editas Medicine: product EDIT-101 worthy of attention

Feng Zhang, who founded Editas Medicine company, in just the past 2018 J. P. Morgan meeting, Editas Medicine, also shared some of the company’s product development information:

• product EDIT-101 in 2018Q3 submitted to the IND application

Products EDIT-101 adapt to the development of disorder is Leber congenital amaurosis diseases, Leber Congenital Amaurosis Type 10, The Company announced at the meeting will be in 2018Q3 submitted to the IND application;

• Recurrent herpes simplex virus infection and Usher syndrome new programme Conference on Editas Medicine at the same time also announced a HSV-1 infection and Usher syndrome new treatment options, and related products have obtained pre-clinical data, is currently in the assessment phase, and will soon publish the latest results.

Editas Medicine is a by the CRISPR/Cas9 technology to build up the company, the gene therapy but also to many rare disease patients to bring new clinical control scheme, the author also here to share Editas Medicine product development pipeline.

Without a doubt, the CRISPR/Cas9 core patent for Editas Medicine, A company has a very important significance, in view of the EP2771468 in Europe were withdrawn, Editas Medicine price micro fall.

*statement: this article by the settled Sina pharmaceutical news authored, the views are those of the authors themselves, does not mean Sina pharmaceutical News Stand.

Published at Tue, 01 Feb 2018 18:49:58 +0000